APIS has obtained a worldwide exclusive license for the commercial development of TROLL-2 and TROLL-3 from Moffitt, setting the groundwork for commercial IVD development of these biomarkers.
Low-level interferon signaling that offers antiviral protection in the absence of active infection is present in all humans shortly after birth, but where and how this signaling occurs has remained unclear. The newly reported work offers up an explanation for this phenomenon.
Caris’ molecular profiling offerings are designed to assess DNA, RNA, and proteins, with the aim of helping physicians and cancer patients make more precise and personalized treatment decisions.
The deep learning model using positron emission tomography/computerized tomography (PET/CT) radiomics may identify which non-small cell lung cancer patients may be sensitive to tyrosine kinase inhibitor treatment and those who would benefit from immune checkpoint inhibitor therapy.
Neurofilament light chain, a promising protein biomarker of neurodegeneration, has been identified in the cerebrospinal fluid and blood as a potential screening tool and prognostic indicator.
The study will support research on health disparities in brain aging and Alzheimer’s between Mexican Americans and non-Latino whites. It is believed that Hispanics are approximately one and one-half times more likely to have Alzheimer’s or other dementias as older whites.
Sponsor: IlluminaIn this Clinical OMICs KEYNOTE webinar, sponsored by Illumina, we are delighted to host two true pioneers of clinical genome sequencing, bioinformatician Dr. Liz Worthey and geneticist Dr. Howard Jacob, who will reflect on a decade of progress in clinical genome analysis and discuss the future challenges confronting the field.
The new partnerships are intended to bolster Thermo Fisher's Precision Medicine Science Center's mission of creating standardized workflows with pharma and academic partners, with the goal of enhancing precision medicine by streamlining the transition from biomarker research to clinical implementation.
By combining available genome-wide association study data and applying mathematical weighting methods, the team found a PRS formula that appears to predict which patients may develop DILI as a result of taking different drugs.
Using induced fluorescence resonance energy transfer (iFRET), the researchers directly assessed interaction between programmed death ligand-1 (PD-L1) ligand with its receptor programmed death receptor-1 (PD-1), in patients’ tumor samples.